2B9-Fc Ameliorates Immune Thrombocytopenia by Suppressing STAT1-Mediated M1 Macrophage Polarization and Expanding Regulatory T Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27219658 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Shuran Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hengyang Medical College, University of South China, Hengyang 421001, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Macrophages, Purpura, Thrombocytopenic, Idiopathic, STAT1 Transcription Factor. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder in which enhanced platelet destruction and impaired platelet production coexist, and a substantial proportion of patients remain refractory to available therapies. Here, we evaluated 2B9-Fc, a thrombopoietin (TPO) mimetic peptide engineered from a cyclic peptide with high affinity for both human and mouse c-MPL, in passive (anti-CD41 monoclonal antibody R300) and active (guinea pig anti-mouse platelet serum, GP-APS) immunization male C57BL/6J and humanized c-MPL receptor transgenic mouse models of ITP. 2B9-Fc (500 μg/kg, subcutaneously) significantly elevated peripheral platelet counts in both models (p < 0.01), without affecting WBC, RBC, or hemoglobin, and alleviated skin purpura and bleeding scores in the active model. In addition, 2B9-Fc treatment was associated with a reduced splenic M1/M2 macrophage ratio, increased regulatory T cells (Tregs), downregulated IL-6 and iNOS while upregulating TGF-β1 and Foxp3, and suppressed STAT1 phosphorylation. In humanized c-MPL receptor transgenic (MT) mice, 2B9-Fc promoted CD41+ megakaryocyte generation in vitro and sustained platelet recovery in vivo through day 14. These results indicate that 2B9-Fc ameliorates ITP and is associated with promotion of megakaryocyte maturation and restoration of immune tolerance, likely involving inhibition of STAT1-mediated M1 polarization and Treg expansion, supporting its potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hengyang Medical College, University of South China, Hengyang 421001, China.
- Academy of Military Medical Sciences, Beijing 100850, China.
- State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.
- College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
- School of Pharmacy, Bengbu Medical University, Bengbu 233030, China.
ORCID-Profile: Shuang Xing, Xing Shen
Zitieren
APA
Yang, S., Xing, S., Shen, X., Zhu, W., Ge, M., Xiao, H., Yu, K., & Yu, Z. (2026). 2B9-Fc Ameliorates Immune Thrombocytopenia by Suppressing STAT1-Mediated M1 Macrophage Polarization and Expanding Regulatory T Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219658
Vancouver
Yang S, Xing S, Shen X, Zhu W, Ge M, Xiao H, et al. 2B9-Fc Ameliorates Immune Thrombocytopenia by Suppressing STAT1-Mediated M1 Macrophage Polarization and Expanding Regulatory T Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219658
BibTeX
@article{Yang2026,
author = {Yang, Shuran and Xing, Shuang and Shen, Xing and Zhu, Wanlu and Ge, Mengting and Xiao, He and Yu, Kaikai and Yu, Zuyin},
title = {2B9-Fc Ameliorates Immune Thrombocytopenia by Suppressing STAT1-Mediated M1 Macrophage Polarization and Expanding Regulatory T Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27219658}
}
EUVIMED